850 chinese COPD patients join study to unlock personalized treatments

NCT ID NCT06724848

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 21 times

Summary

This study is observing 850 people with COPD in China to understand how the disease progresses and what factors affect it. Researchers will collect medical history, lung function tests, and blood samples over 1 to 3 years. The goal is to identify different types of COPD and find clues that could lead to more personalized treatments in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    NOT_YET_RECRUITING

    Beijing, China

  • Research Site

    NOT_YET_RECRUITING

    Changsha, China

  • Research Site

    NOT_YET_RECRUITING

    Chengdu, China

  • Research Site

    RECRUITING

    Guangzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Hefei, China

  • Research Site

    NOT_YET_RECRUITING

    Nanjing, China

  • Research Site

    NOT_YET_RECRUITING

    Nanning, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, China

  • Research Site

    NOT_YET_RECRUITING

    Xuzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Zhengzhou, China

Conditions

Explore the condition pages connected to this study.